Pharmaids Pharmaceuticals Limited has announced the completion of Mr. Mopperthy Sudheer's term as Independent Director, effective from January 05, 2026. The pharmaceutical company informed BSE Limited through a regulatory filing under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Director Term Completion Details

Mr. Mopperthy Sudheer (DIN: 00404917) ceased to hold office as Independent Director with effect from the close of business hours on January 05, 2026, upon completion of his directorship term. The company's filing, signed by Company Secretary & Compliance Officer Prasanna Subramanya Bhat, provided comprehensive details as required under regulatory guidelines.

Committee Membership Changes

Consequent to Mr. Sudheer's completion of his directorship term, he also ceased to be a member of key board committees. The director was serving on both the Audit Committee and Nomination & Remuneration Committee prior to his term completion.

Regulatory Compliance

The disclosure was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company provided detailed information in compliance with SEBI Master Circular dated November 11, 2024, ensuring full transparency regarding the board composition change.

The regulatory filing included comprehensive details covering the director's name, reason for cessation, effective date, and other particulars as mandated by SEBI regulations. The company maintained proper compliance protocols by informing the stock exchange within the prescribed timeframe and providing all necessary documentation.

Pharmaids Pharmaceuticals Limited has announced the reconstitution of its Board Committees through a circular resolution passed on January 05, 2026. The pharmaceutical company informed the stock exchanges about these governance changes, which will take effect from January 06, 2026, in compliance with regulatory requirements.

Board Committee Restructuring

The company's Board of Directors approved the reconstitution of two key committees as part of its governance framework. This restructuring demonstrates the company's commitment to maintaining robust corporate governance standards and ensuring effective oversight mechanisms.

Audit Committee Composition

The reconstituted Audit Committee features a comprehensive structure with four members, maintaining a strong independent director presence:

The Audit Committee maintains its critical role in overseeing financial reporting, internal controls, and audit processes, with three independent directors ensuring objective oversight.

Nomination & Remuneration Committee Structure

The Nomination & Remuneration Committee has been reconstituted with three independent directors, ensuring complete independence in key personnel and compensation decisions:

This committee structure aligns with best practices in corporate governance, with Mr. Methuku Nagesh taking the leadership role as Chairman.

Regulatory Compliance

The reconstitution has been undertaken pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has formally communicated these changes to BSE Limited, ensuring full transparency and regulatory compliance. The circular resolution mechanism demonstrates efficient decision-making processes within the company's governance framework.